Pharmaceuticals

JACOBSON PHARMA

Jacobson Pharma released FY2026 Q1 earnings on November 18, 2025 (BJT) with actual revenue of HKD 383.28 M and EPS of HKD 0.0356

Jacobson Pharma released FY2026 Q2 earnings on November 18 Pre-Market BJT, actual revenue HKD 383.28 M, actual EPS HKD 0.0355

Jacobson Pharma released FY2026 Semi-Annual Earnings on November 18 Pre-Market (BJT), with actual revenue of HKD 766.55 M and EPS of HKD 0.0711

Jacobson Pharma to Release FY2026 Semi-Annual Earnings on November 18, 2025 (BJT)

Jacobsen and Jianbeimiao Subsidiaries Sign Factory Usage Licensing Agreement

Jacob 臣 Scientific Pharmaceuticals Signs New 2025 Europharm Licensing Agreement

Jacobsen Research Proposes Special Dividend

Yorken Scientific Pharmaceuticals Announces Continuous Growth in Annual Report

Jacob 臣 Research Pharmaceuticals reports over HK$1.5 billion in revenue for FY2025, profit up 12.69%

Jacobson Pharma released FY2025 9 Months Earnings on June 13 (BJT), actual revenue HKD 1.193 B, actual EPS HKD 0.111

Jacobson Pharma released FY2025 Q3 earnings on June 13 (BJT), actual revenue HKD 383.45M, actual EPS HKD 0.0403

Jacobson Pharma released FY2025 earnings on June 13 After-Market (BJT), actual revenue HKD 1.577 B (forecast HKD 141 M), actual EPS HKD 0.1514

Jacobson Pharma released FY2025 Q4 earnings on June 13 After-Market (BJT), actual revenue HKD 383.45 M, actual EPS HKD 0.0403

Yaokeshen Scientific Pharmaceutical Reports 24.5% Profit Growth for FY 2025

JACOBSEN Proposes Final Dividend of HKD 0.055 Per Share

Jacob 臣 Research Pharmaceutical Releases Earnings Growth Forecast

Prof. Lam Wing Keung to Retire as Independent Non-Executive Director of Yakult Scientech

Jacobson Pharma to Release FY2025 Earnings on June 13 After-Market (BJT), Forecast Revenue HKD 141 M

Jacobsen Pharma Projects Over 40% Profit Growth in FY2025

Queenshill Development Limited Increases Stake in Jacobson Pharmaceutical by 200 Million Shares

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02633

UOB Kay Hian analyst maintained a Buy rating on Jacobson Pharma Corporation Limited yesterday and set a price target of HK$2.45.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Jacobson Pharma Corporation Limited has an analyst consensus of Moderate Buy, with a price target consensus of HK$2.45.

Tip Ranks

UOB Kay Hian

UOB Kay Hian Sticks to Its Buy Rating for Jacobson Pharma Corporation Limited (2633)

JACOBSON PHARMA announced that it has signed a contract with Ruian to invest approximately HKD 607 million in the construction of specific infrastructure and facilities at the Tai Po Innovation Park. The project is expected to be completed within 745 days, with plans to acquire the pharmaceutical facilities in Tai Po Industrial Estate in 2025, establishing 10 new smart production lines that utilize AI and robotic technology to meet local and global medical needs

AASTOCKS

JACOBSON PHARMA invested 600 million yuan to establish a factory in Tai Po

512290

589720

513700

JBM Healthcare and Jacobson Pharma Renew Connected Logistics Framework Through 2029

Guotai CSI Bio-medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Universal 800 Health Care ETF

JBM Healthcare and Jacobson Pharma Renew Connected Logistics Framework Through 2029

JACOBSON PHARMA announced its interim results for the six months ended September, with revenue of HKD 767 million, a year-on-year decrease of 5.4%. It recorded a net profit of HKD 142 million, an increase of 1.2%, with earnings per share of HKD 0.0712. The interim dividend is HKD 0.0425, compared to HKD 0.035 in the same period last year

"Performance" Jacobson Pharma's interim net profit is HKD 142 million, an increase of 1.2%, with a dividend of 4.25 cents

Jacobson Pharma Corporation Limited reported a 5.4% revenue decrease to HK$766.6 million for the six months ending 30 September 2025. Despite this, profit attributable to shareholders rose by 1.2% to HK$142.0 million. The Board declared an interim dividend of HK4.25 cents per share, a 21.4% increase from the previous year. The stock is rated Hold with a HK$1.50 price target. Jacobson Pharma focuses on generic drugs and proprietary medicines, listed on the Hong Kong Stock Exchange under code 2633.

Jacobson Pharma Reports Interim Results with Increased Shareholder Dividends

JACOBSON PHARMA and Jianbei Miao Miao announced the signing of a licensing agreement with Europharma (Hong Kong) for 2025, allowing the use of certain factories, with a term from December 1, 2025, to January 27, 2028, and a monthly licensing fee of HKD 247,000. This agreement will bring rental income to Europharma and provide manufacturing space for Europharma (Hong Kong), avoiding high relocation costs

Zhitong

JACOBSON PHARMA and Jianbei Miao Miao: Europharma and Europharma (Hong Kong) entered into a 2025 licensing agreement with Europharma

According to the Zhitong Finance APP, JACOBSON PHARMA announced that Lu Tinglong has been appointed as the company's independent non-executive director and a member of the company's audit committee, as well as the chairman of the risk management committee and the environmental, social, and governance committee, effective from July 28, 2025, following Professor Lin's resignation. The company's executive director, Mr. Yan Zhenliang, has resigned as a member of the company's nomination committee, while the company's executive director, Ms. Pan Yuhui, has been appointed as a member of the company's nomination committee, effective from July 28, 2025

JACOBSON PHARMA: Lu Tinglong appointed as independent non-executive director

JACOBSON PHARMA(02633.HK)

UOB Kay Hian Sticks to Its Buy Rating for Jacobson Pharma Corporation Limited (2633)

JACOBSON PHARMA invested 600 million yuan to establish a factory in Tai Po

JBM Healthcare and Jacobson Pharma Renew Connected Logistics Framework Through 2029

"Performance" Jacobson Pharma's interim net profit is HKD 142 million, an increase of 1.2%, with a dividend of 4.25 cents

Jacobson Pharma Reports Interim Results with Increased Shareholder Dividends

JACOBSON PHARMA and Jianbei Miao Miao: Europharma and Europharma (Hong Kong) entered into a 2025 licensing agreement with Europharma

JACOBSON PHARMA: Lu Tinglong appointed as independent non-executive director